Here's Why CLOV Stock is Undervalued (High Growth Stock)

What I’m seeing amidst all of this selling is a sweet opportunity in CLOV stock. In this video we are going to cover the short seller allegations against Clover & we will be taking a look at the company, what they do, the financials and the competition. Many say it has the potential to 2x in the next few weeks, but does it?  Few weeks ago, Hindenburg, the famous short seller, accused Chamath, the “king of spacs”, of luring retail investors through CLOV. Chamath is known for finding insane growth opportunities and has helped many great companies go public such as Virgin Galactic. Chamath has a reputation to keep up so I don’t think he would jeopardize that with a crappy company. But of course, this is something we need to verify ourselves, so now let’s take a look at Clover Health. Clover uses a software, named the Clover Assistant, that improves every interaction at the point of care. Clover assistance is a combination of machine learning and an expert system. Physicians currently use clover assistants to help them deliver better care to patients, which gives better outcomes to patients and physicians as well. The company currently manages Medicare advantage plans and receives roughly $10,000 in annual revenue per patient. There are plenty of good reasons to buy shares of Clover Health right now, but it's important to remember this is a small company competing against giants like UnitedHealth Group and Teladoc. It sure looks like Clover Health has what it takes to grow its membership base by hundreds or even thousands, but any signs of stagnation over the next several quarters could cause investors to cut and run. That’s the risk of this investment. CLOV has Chamath leadership & endorsement. In my opinion, I see the stock running up 2x in the medium-short term.